Cargando…

AstraZeneca COVID-19 vaccine: EMA continues review of rare blood clots

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035857/
http://dx.doi.org/10.1007/s40278-021-93807-0
_version_ 1783676788551974912
collection PubMed
description
format Online
Article
Text
id pubmed-8035857
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-80358572021-04-12 AstraZeneca COVID-19 vaccine: EMA continues review of rare blood clots Reactions Weekly News Item Springer International Publishing 2021-04-10 2021 /pmc/articles/PMC8035857/ http://dx.doi.org/10.1007/s40278-021-93807-0 Text en © Springer International Publishing AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle News Item
AstraZeneca COVID-19 vaccine: EMA continues review of rare blood clots
title AstraZeneca COVID-19 vaccine: EMA continues review of rare blood clots
title_full AstraZeneca COVID-19 vaccine: EMA continues review of rare blood clots
title_fullStr AstraZeneca COVID-19 vaccine: EMA continues review of rare blood clots
title_full_unstemmed AstraZeneca COVID-19 vaccine: EMA continues review of rare blood clots
title_short AstraZeneca COVID-19 vaccine: EMA continues review of rare blood clots
title_sort astrazeneca covid-19 vaccine: ema continues review of rare blood clots
topic News Item
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035857/
http://dx.doi.org/10.1007/s40278-021-93807-0